Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Could Outpatient Cell Therapies Provide Way Out Of Bundled Payment Trap?

Cell Therapies Increasingly Developed With Outpatient Use In Mind

Executive Summary

Giving cell therapies as outpatient rather than inpatient treatments could be a way around the need for bundled payments, but it’s not universally applicable.

You may also be interested in...



New Data Brings Yescarta Closer To Blockbuster Territory

Gilead announced positive topline results from the ZUMA-7 trial of Yescarta in second-line large B-cell lymphoma, where the CAR-T would eventually compete with BMS’s Breyanzi and Novartis’ Kymriah.

Allogene CAR-Ts’ Durability Remains A Question, But Strong Data So Far

Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.

As CAR-Ts Proliferate, CMS Seeks To Reserve Medicare Add-On Payments For ‘New’ Therapies

Products from Bristol-Myers Squibb, Gilead and J&J might be eligible for supplemental reimbursement under hospital payment proposed rule that could help promote uptake.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel